We are very pleased that both professors have accepted to be engaged with Arcede Pharma as advisors. Their proven experience and expertise in the field will strengthen the further development of RCD405. The collaboration will ensure that our plans are critically scrutinised and will help refine our development strategies. This will be of great importance, especially in the phase where RCD405 is to enter the clinical phase once the regulatory toxicological program has been completed and finalised. Professor Clive Page has an extensive and proven track record within the area of pharmacology with focus on inflammation and respiratory disease as well as an in-depth knowledge from the pharmaceutical industry. Professor Arne Egesten contributes with his long clinical experience within pulmonary medicine in addition to his research career within chronic airway inflammation, based on both experimental, clinical and epidemiological studies, where the aim is to define new and improved treatment principles and thereby reduce people's suffering and increase their quality of life.

For more information:
Mia Lundblad, CEO
Arcede Pharma AB 
mia.lundblad@arcedepharma.com 
+46 723 12 27 44

The information was submitted for publication on January 18, 2023.

About Arcede Pharma
Arcede Pharma is aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients. Chronic obstructive pulmonary disease (COPD) is a disease that has a substantial negative impact on patients and causes a lot of suffering. COPD is the third most common cause of death worldwide. For more information: www.arcedepharma.com.